Innovating highly efficacious,
toxicity-free small molecules
for metastasized cancers

Innovating Bio-Particle
Therapeutics of Small Molecules

Vopec Pharmaceuticals and Agastiya Biotech Announce Breakthrough Phase 1 Study Results of Small Molecule AB001 for Multiple Metastatic Solid Tumors

Vopec Pharmaceuticals and Agastiya Biotech announce results from the Phase 1 study of AB001, an investigational small molecule PDL1 immunotherapy for patients with metastasized and locally advanced solid tumors.  Unlike current standard-of-care immuno- and chemotherapy drugs AB001’s novel immunotherapy mechanism of action selectively destroys tumors without harming healthy cells.  Read more on the breakthrough toxicity and efficacy of AB001 on multiple metastatic cancers.

The US FDA has awarded Orphan Drug Designations for Glioblastoma, Pancreatic and Acute Myeloid Leukemia indications for AB001.   These rare cancers are generally considered a death sentence.  AB001 may prove to be the answer.

At Agastiya we create negligibly / toxicity-free small molecules, an unmet need of the pharmaceutical industry. Toxicity is the biggest challenge in drug discovery. It not only delays the drug approval process but results in less efficacy and drives up drug costs.

Our impressive portfolio of small molecules has no toxicity/negligible toxicity covering a wide variety of cancer indications, neurodegenerative diseases such as Alzheimer’s, Parkinson’s, dementia, depression, diabetes, life extension telomere technology, and others.


Pharma pricing has been the biggest issue debated by the US lawmakers, White House and general public. Agastiya Biotech’s strategy to “Make in India” will be beneficial for the US to cut cost and at the same time will be a great financial opportunity for India.

Our Programs

Anti-viral Therapeutics for Sars-Cov-2

Agastiya Biotech has studied its previously tested anti-cancer small molecule AB001 blocks Sars-CoV-2 virus therapeutics in silico studies.

Cancer Drug

We are developing novel molecular formulations for breakthrough therapies in cancer stem cells, tumor supressor genes and oncogene mutations.


Psoriais is a chronic, immune-mediated, inflammatory relapsing systemic skin disorder that predominantly involves the skin, nails, and joints with intermittent.

Discovery Renaissance

We’re identifying the undeniable synergy between
neurons, nature and genetics overlaid
with time tested algorithms.